Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$36.99-2.8%$43.10$36.52▼$68.39$3.26B1.771.55 million shs1.60 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics-2.76%-10.26%-16.69%-7.57%-47.28%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics3.4089 of 5 stars4.22.00.00.02.83.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.48Hold$73.1197.64% UpsideCurrent Analyst Ratings BreakdownLatest CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/19/2025CRSPCRISPR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral2/18/2025CRSPCRISPR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$89.00 ➝ $82.002/14/2025CRSPCRISPR TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderweight ➝ Underweight$30.00 ➝ $32.002/14/2025CRSPCRISPR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeIn-Line ➝ Outperform$60.00 ➝ $99.002/13/2025CRSPCRISPR TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$66.00 ➝ $57.002/13/2025CRSPCRISPR TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$53.00 ➝ $49.002/13/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.00 ➝ $86.002/13/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$94.00 ➝ $84.002/13/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.00 ➝ $65.002/12/2025CRSPCRISPR TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$100.00 ➝ $120.00(Data available from 3/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$35M90.65N/AN/A$22.52 per share1.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.37N/AN/AN/A-981.54%-18.46%-15.79%5/6/2025 (Estimated)Latest CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/11/2025Q4 2024CRSPCRISPR Therapeutics-$1.15-$0.44+$0.71-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A22.0722.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics47385.77 million82.26 millionOptionableCRSP HeadlinesRecent News About These CompaniesIQ EQ FUND MANAGEMENT IRELAND Ltd Has $1.43 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)March 29 at 5:47 AM | marketbeat.comLoomis Sayles & Co. L P Lowers Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)March 29 at 5:47 AM | marketbeat.comPromising Genomics & Synthetic Biology Stocks to Consider in 2025March 28 at 10:41 AM | zacks.comRaymond James Financial Inc. Takes $3.23 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP)March 28 at 3:21 AM | marketbeat.comCRISPR Therapeutics (NasdaqGM:CRSP) COO Departure Announced Following 7% Share Price DeclineMarch 27 at 6:25 PM | finance.yahoo.comCRISPR Therapeutics AG: CRISPR Therapeutics Announces Transition of Chief Operating OfficerMarch 27 at 8:23 AM | finanznachrichten.deCrispr Therapeutics COO Julianne Bruno to step downMarch 27 at 8:23 AM | markets.businessinsider.comCrispr Therapeutics Operating Chief Julianne Bruno to Step DownMarch 26 at 11:48 PM | marketwatch.comCRISPR Therapeutics Announces Transition of Chief Operating OfficerMarch 26 at 4:01 PM | globenewswire.comThis CRISPR Therapeutics Insider Increased Their Holding In The Last YearMarch 26 at 8:30 AM | finance.yahoo.comAvantax Advisory Services Inc. Purchases New Position in CRISPR Therapeutics AG (NASDAQ:CRSP)March 26 at 3:24 AM | marketbeat.comHighTower Advisors LLC Decreases Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)March 26 at 3:23 AM | marketbeat.comIs CRISPR Therapeutics AG (CRSP) a Promising Biotech Stock According to Wall Street AnalystsMarch 25, 2025 | msn.comCRISPR Therapeutics Set To Reach Previous HeightsMarch 25, 2025 | seekingalpha.comCRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on ItMarch 25, 2025 | zacks.comMagnetar Financial LLC Buys New Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)March 24, 2025 | marketbeat.comStockNews.com Upgrades CRISPR Therapeutics (NASDAQ:CRSP) to SellMarch 23, 2025 | americanbankingnews.com2 Beaten-Down Stocks to Buy on the DipMarch 22, 2025 | fool.comCRISPR Therapeutics (NASDAQ:CRSP) and MeiraGTx (NASDAQ:MGTX) Head to Head ComparisonMarch 22, 2025 | americanbankingnews.comCRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth KnowingMarch 21, 2025 | zacks.comContrarius Group Holdings Ltd Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)March 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$36.99 -1.05 (-2.76%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$36.90 -0.09 (-0.24%) As of 03/28/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Microsoft’s Big Malaysia Bet Could Pay Off for Investors Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
